Altech secures site for HPA plant, shares up 9%

|

Published 01-OCT-2015 09:16 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Altech Chemicals (ASX:ATC) has followed-up its game-changing announcement that Mitsubishi would act as its sales agent with news that it had secured land for its high purity alumina (HPA) plant in Malaysia.

ATC has reserved a spot in the Tanjung Langsat Industrial Complex for its plant, with an option to lease the site for 30 years.

It is aiming to build a full-scale 4000 tonnes per annum alumina, to produce high-quality alumina for industrial customers in Asia.

ATC told shareholders today that it had selected the site because it had easy access to vital materials such as hydrochloric acid, limestone, quicklime, power, and natural gas.

The site also has the availability of skilled labour, and ATC said it anticipates building costs will be 40% lower than an equivalent plant in Western Australia.

The site is also on an international sea container port, making export of the product an easier exercise.

News of the land reservation sent ATC shares up over 9% nearing the close of trade yesterday, above the broader All Ordinaries gain of 1.8%.

The Altech play

ATC is aiming to mine a 65 million tonnes JORC-compliant aluminous clay in WA to be processed at an advanced beneficiation plant at Meckering, with the aim of producing 25,000t of alumina-rich kaolin clay per year.

This clay will be taken to a full-scale 4000tpa HPA production plant, using its technology to produce a 99.99% pure HPA product.

Recently it signed up industrial giant Mitsubishi to act as a sales agent for its finished product, giving ATC an entry into the lucrative Japanese market.

ATC has previously told investors that Japan accounted for 21% of HPA demand in 2014.

Mitsubishi is Japan’s largest general trading company, with more than 200 bases in about 90 countries around the world, including Australia.

The big growth market ATC is targeting is the consumer electronics manufacturer sector, which is increasingly using this advanced product in smart phones, tablets and laptops.

HPA can be used to make artificial sapphires, which can be turned into Sapphire Glass, a much more durable and scratch resistant material than the usual Gorilla Glass most of these products use.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X